Literature DB >> 23257395

Familial aggregation of circulating C-reactive protein in polycystic ovary syndrome.

Arunachalam Sasidevi1, Priyathama Vellanki, Allen R Kunselman, Nazia Raja-Khan, Andrea Dunaif, Richard S Legro.   

Abstract

STUDY QUESTION: What is the heritability of C-reactive protein (CRP) levels in women with polycystic ovary syndrome (PCOS) and their first-degree relatives? SUMMARY ANSWER: Women with PCOS and their siblings are more likely to have elevated CRP levels when both of their parents have elevated CRP. This PCOS family-based study indicates that CRP levels are likely a heritable trait. WHAT IS KNOWN ALREADY: Previous studies have established that an elevated blood level of CRP is variably present in women with PCOS, and may be present independent of metabolic status. STUDY DESIGN, SIZE AND DURATION: A familial based phenotyping study consisting of 81 families comprised of PCOS patients and their first-degree relatives for 305 subjects. PARTICIPANTS/MATERIALS, SETTING AND METHODS: Study conducted at an academic health center. An elevated CRP level was defined as >28.6 nmol/l. To account for familial clustering, generalized estimating equations with a logit link were used to model the association between elevated CRP levels in patients with PCOS and their siblings with their parental group (A = neither parent with elevated CRP; B = one parent with elevated CRP; C= both parents with elevated CRP), adjusting for gender, age and BMI of the offspring. We did additional heritability analyses by using a variance component estimation method for CRP levels, adjusting for sex, age and BMI. MAIN RESULTS AND THE ROLE OF CHANCE: We observed elevated CRP levels in 94% of the offspring in group C, 45% in group B and 10% in group A after adjusting for age, gender and BMI of the offspring. The median BMI of the offspring in group A, B and C were 30.0, 28.7 and 31.2 kg/m², respectively. Heritability estimates of CRP levels ranged from 0.75 to 0.83 and remained significant after excluding for type 2 diabetes mellitus. Our small sample size increases the possibility of a type 1 error. LIMITATIONS, REASONS FOR CAUTION: This is a single report in an adequately powered but limited sample size study identifying the strong heritability of CRP levels. Replication in other large family cohorts is necessary. WIDER IMPLICATION OF THE
FINDINGS: These findings support the concept that there is an increased cardiovascular disease risk profile in families of women with PCOS. STUDY FUNDING/COMPETING INTEREST: This research was supported by National Institutes of Health grants U54HD-034449 and P50 HD044405 (A.D.). Priyathama Vellanki is supported in part by NIH/NIDDK Training Grant T32 DK007169.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23257395      PMCID: PMC3571499          DOI: 10.1093/humrep/des416

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  28 in total

1.  Multipoint quantitative-trait linkage analysis in general pedigrees.

Authors:  L Almasy; J Blangero
Journal:  Am J Hum Genet       Date:  1998-05       Impact factor: 11.025

2.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.

Authors:  P M Ridker; C H Hennekens; J E Buring; N Rifai
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

3.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

4.  Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study.

Authors:  J S Pankow; A R Folsom; M Cushman; I B Borecki; P N Hopkins; J H Eckfeldt; R P Tracy
Journal:  Atherosclerosis       Date:  2001-02-15       Impact factor: 5.162

5.  Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

Authors:  D A Ehrmann; R B Barnes; R L Rosenfield; M K Cavaghan; J Imperial
Journal:  Diabetes Care       Date:  1999-01       Impact factor: 19.112

6.  Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.

Authors:  R S Legro; D Driscoll; J F Strauss; J Fox; A Dunaif
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

7.  Evidence for a single gene effect causing polycystic ovaries and male pattern baldness.

Authors:  A H Carey; K L Chan; F Short; D White; R Williamson; S Franks
Journal:  Clin Endocrinol (Oxf)       Date:  1993-06       Impact factor: 3.478

8.  C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women.

Authors:  Paul M Ridker; Julie E Buring; Nancy R Cook; Nader Rifai
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

9.  The prevalence and features of the polycystic ovary syndrome in an unselected population.

Authors:  Ricardo Azziz; Keslie S Woods; Rosario Reyna; Timothy J Key; Eric S Knochenhauer; Bulent O Yildiz
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

10.  Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease.

Authors:  N Boulman; Y Levy; R Leiba; S Shachar; R Linn; O Zinder; Z Blumenfeld
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

View more
  1 in total

Review 1.  Life Modifications and PCOS: Old Story But New Tales.

Authors:  Yuanyuan Gu; Guannan Zhou; Fangyue Zhou; Qiongwei Wu; Chengbin Ma; Yi Zhang; Jingxin Ding; Keqin Hua
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-13       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.